Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer. Phase I Feasibility Study of Hifu-Induced Hyperthermia, LTLD and Cyclophosphamide for Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Doxorubicin liposomal (Primary)
Indications Advanced breast cancer
Focus Adverse reactions
Acronyms i-GO

Most Recent Events

02 Nov 2020 Planned End Date changed from 1 Mar 2022 to 1 Nov 2022.
02 Nov 2020 Planned primary completion date changed from 1 Mar 2022 to 1 Nov 2022.
02 Nov 2020 Planned initiation date(estimated date for recruitment of the first subject) changed to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight